Viz.ai Receives FDA 510(k) Clearance for Viz ANEURYSM

Viz.ai, the world leader in artificial intelligence (AI) powered care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz ANEURYSM. SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the world leader in artificial intelligence (AI) powered care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Viz ANEURYSM. Viz ANEURYSM will serve as a first of its kind population health tool to facilitate population screening and enhanced care management. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis. Also in 2021, the FDA cleared the Viz PE and Viz Aortic modules, making the Viz Platform multi-disciplinary.